OKYO Pharma Ltd (OKYO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OKYO Profit Margin, ROE & Profitability Analysis
OKYO vs Healthcare Sector: How OKYO Pharma Ltd Compares
How OKYO Pharma Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OKYO Pharma Ltd Stock Overvalued? OKYO Valuation Analysis 2026
Based on fundamental analysis, OKYO Pharma Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OKYO Pharma Ltd Balance Sheet: OKYO Debt, Cash & Liquidity
OKYO Revenue Growth, EPS Growth & YoY Performance
OKYO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OKYO Pharma Ltd (CIK: 0001849296)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OKYO
What is the AI rating for OKYO?
OKYO Pharma Ltd (OKYO) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OKYO's key strengths?
Claude: Analysis in progress.
What are the risks of investing in OKYO?
Claude: Analysis in progress.
What is OKYO's revenue and growth?
OKYO Pharma Ltd reported revenue of N/A.
Does OKYO pay dividends?
OKYO Pharma Ltd does not currently pay dividends.
Where can I find OKYO SEC filings?
Official SEC filings for OKYO Pharma Ltd (CIK: 0001849296) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OKYO's EPS?
OKYO Pharma Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OKYO's fundamental grade?
Based on our AI fundamental analysis in July 2026, OKYO Pharma Ltd has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OKYO stock overvalued or undervalued?
Valuation metrics for OKYO: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OKYO's AI grade for 2026?
Our dual AI analysis gives OKYO Pharma Ltd a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OKYO's free cash flow?
OKYO Pharma Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does OKYO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).